Rituximab in indolent lymphomas

Seminars in Hematology

Volumn 47, Issue 2, 2010, Pages 133-142

  Sousou, Tarek ^a   Friedberg, Jonathan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSTIMULATING AGENT; INTERFERON; METHOTREXATE; MITOXANTRONE; PLACEBO; PREDNISONE; RITUXIMAB; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LEUKOPENIA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MARGINAL ZONE LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FORECASTING; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 77950325643     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.01.003     Document Type: Article

References (55)

1. Ardeshna K.M., Smith P., Norton A., et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003, 362:516-522.
2. Horning S.J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993, 20:75-88.
3. Johnson P.W., Rohatiner A.Z., Whelan J.S., et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995, 13:140-147.
4. Montoto S., López-Guillermo A., Ferrer A., et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol 2002, 13:523-530.
5. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89:3909-3918. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.
6. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
7. Friedberg J.W., Taylor M.D., Cerhan J.R., et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009, 27:1202-1208.
8. Fisher R.I., LeBlanc M., Press O.W., Maloney D.G., Unger J.M., Miller T.P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23:8447-8452.
9. Liu Q., Fayad L., Cabanillas F., et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006, 24:1582-1589.
10. Pulte D., Gondos A., Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008, 168:469-476.
11. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
12. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101-106.
13. Colombat P., Brousse N., Morschhauser F., et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F/Up) of 7 years [abstract]. ASH Annual Meeting Abstracts 2006, 108:486.
14. Freedman A., Neelapu S.S., Nichols C., et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009, 27:3036-3043.
15. Ezdinli E.Z., Harrington D.P., Kucuk O., Silverstein M.W., Anderson J., O'Connell M.J. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 1987, 60:156-160.
16. Hagenbeek A., Carde P., Meerwaldt J.H., et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998, 16:41-47.
17. Rohatiner A., Radford J., Deakin D., et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001, 85:29-35.
18. Steward W.P., Crowther D., McWilliam L.J., et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988, 61:441-447.
19. Davis T.A., Grillo-López A.J., White C.A., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135-3143.
20. Igarashi T., Ohtsu T., Fujii H., et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001, 73:213-221.
21. Hainsworth J.D., Litchy S., Burris H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:4261-4267.
22. Hainsworth J.D., Litchy S., Shaffer D.W., Lackey V.L., Grimaldi M., Greco F.A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088-1095.
23. Ghielmini M., Schmitz S.-F.H., Cogliatti S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004, 103:4416-4423.
24. Berinstein N.L., Grillo-Lopez A.J., White C.A., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998, 9:995-1001.
25. Ghielmini M.E., Hsu Schmitz S., Martinelli G., et al. Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98 [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:8512.
26. Taverna C.J., Bassi S., Hitz F., et al. First results of long-term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03 [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:8534.
27. Czuczman M.S., Olejniczak S., Gowda A., et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008, 14:1561-1570.
28. Czuczman M.S., Grillo-Lopez A.J., White C.A., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-276.
29. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
30. Czuczman M.S., Weaver R., Alkuzweny B., Berlfein J., Grillo-Lopez A.J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711-4716.
31. Chow K.V., Carroll R., Branley P., Nicholls K., Becker G., Hogan C. Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Int Med J 2007, 37:329-332.
32. Rose A.L., Smith B.E., Maloney D.G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002, 100:1765-1773.
33. Herold M., Haas A., Srock S., et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study. J Clin Oncol 2007, 25:1986-1992.
34. Di Gaetano N., Xiao Y., Erba E., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001, 114:800-809.
35. Czuczman M.S., Koryzna A., Mohr A., et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005, 23:694-704.
36. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
37. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706-714.
38. Buske C., Hoster E., Dreyling M., et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009, 23:153-161.
39. Treon S.P., Branagan A.R., Ioakimidis L., et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009, 113:3673-3678.
40. Nichols G.L., Savage D.G. Timing of rituximab/fludarabine in Waldenstrom's macroglobulinemia may avert hyperviscosity [abstract]. ASH Annual Meeting Abstracts 2004, 104:4612.
41. Conconi A., Martinelli G., Thiéblemont C., et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003, 102:2741-2745.
42. Brown J.R., Friedberg J.W., Feng Y., et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009, 145:741-748.
43. van Oers M.H.J., Klasa R., Marcus R.E., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-3301.
44. Van Oers M.H.J., Van Glabbeke M., Baila L., et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study [abstract]. ASH Annual Meeting Abstracts 2008, 112:836.
45. Hochster H., Weller E., Gascoyne R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009, 27:1607-1614.
46. Friedberg J.W., Freedman A.S. Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. Curr Treat Opt Oncol 2006, 7:276-284.
47. Friedberg J.W., Neuberg D., Gribben J.G., et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002, 117:828-834.
48. Gluck W.L., Hurst D., Yuen A., et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004, 10:2253-2264.
49. Davis T.A., Maloney D.G., Grillo-Lopez A.J., et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000, 6:2644-2652.
50. Ansell S.M., Witzig T.E., Kurtin P.J., et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002, 99:67-74.
51. Friedberg J.W., Kim H., McCauley M., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105:489-495.
52. Friedberg J.W., Kelly J.L., Neuberg D., et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009, 146:282-291.
53. Leonard J.P., Link B.K., Emmanouilides C., et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007, 13:6168-6174.
54. Friedberg J.W. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology 2005, 2005:329-334.
55. Ghielmini M., Rufibach K., Salles G., et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005, 16:1675-1682.